Last reviewed · How we verify

Adjuvant letrozole (postmenopausal women) (adjuvant-letrozole-postmenopausal-women)

Pfizer · FDA-approved active Quality 40/100

Adjuvant letrozole (postmenopausal women) (generic name: adjuvant-letrozole-postmenopausal-women) is a aromatase inhibitor drug developed by Pfizer. It is currently FDA-approved for Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy.

Adjuvant letrozole is a marketed drug by Pfizer Inc. for postmenopausal women with hormone receptor-positive invasive breast cancer. It is used after 2-3 years of tamoxifen therapy. The mechanism of action is not specified in the provided information. Adjuvant letrozole is a key treatment option for this patient population. It has generated significant revenue of $21.2B. The drug has undergone 31 clinical trials.

At a glance

Generic nameadjuvant-letrozole-postmenopausal-women
SponsorPfizer
Drug classaromatase inhibitor
Targetaromatase
Therapeutic areaOncology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adjuvant letrozole (postmenopausal women)

What is Adjuvant letrozole (postmenopausal women)?

Adjuvant letrozole (postmenopausal women) (adjuvant-letrozole-postmenopausal-women) is a aromatase inhibitor drug developed by Pfizer, indicated for Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy.

What is Adjuvant letrozole (postmenopausal women) used for?

Adjuvant letrozole (postmenopausal women) is indicated for Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy.

Who makes Adjuvant letrozole (postmenopausal women)?

Adjuvant letrozole (postmenopausal women) is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Adjuvant letrozole (postmenopausal women)?

adjuvant-letrozole-postmenopausal-women is the generic (nonproprietary) name of Adjuvant letrozole (postmenopausal women).

What drug class is Adjuvant letrozole (postmenopausal women) in?

Adjuvant letrozole (postmenopausal women) belongs to the aromatase inhibitor class. See all aromatase inhibitor drugs at /class/aromatase-inhibitor.

What development phase is Adjuvant letrozole (postmenopausal women) in?

Adjuvant letrozole (postmenopausal women) is FDA-approved (marketed).

What does Adjuvant letrozole (postmenopausal women) target?

Adjuvant letrozole (postmenopausal women) targets aromatase and is a aromatase inhibitor.

Related